Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
For more than 25 years, advances have been made in developing medications to treat alcohol use disorder (AUD), highlighted by the U.S. Food and Drug Administration's approval of naltrexone (oral and long-acting) and acamprosate. Despite this progress, more work remains to be done in this area because these medications, although effective for some people, do not work for everyone. A high priority for the National Institute on Alcohol Abuse and Alcohol is to put into place a solid infrastructure to aid in the development of medications that are more effective than those currently available and with few side effects. Medication development, especially for a disorder as complex as AUD, is challenging and involves multiple phases, including discovery of "druggable" targets, preclinical studies, human clinical trials, and the adoption and implementation of the new medication into mainstream medicine. A successful medications development program requires clearly established goals for each phase to ensure that a candidate compound is not trapped in one particular phase, a condition known as "the valley of death." In this article, the phases of medication development are described as they apply to AUD, and specific goals of each phase are identified for the next decade. In addition, several important crosscutting themes are outlined for each phase, all of which are essential for advancing medications development. These include identifying and validating screening models and druggable targets, making use of precision medicine, and establishing partnerships among key stakeholders. Our goal in writing this article is to provide a guide on medications development that will aid the alcohol research community in planning, testing, and developing medications for AUD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“Nearly, half of the cost of drug development is spent in conducting clinical trials (Paul et al., 2010).”
Grant, B. F., Goldstein, R. B., Saha, T. D., Chou, S. P., Jung, J., Zhang, H., Pickering, R. P., Ruan, W. J., Smith, S. M., Huang, B., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0584 · Cited by 2,556 · cited 1×
“ALCOHOL USE DISORDER (AUD) is a complex anddevastating disease, affecting 13.9% of Americans in a 1-year period and resulting in a range of medical, psychological, social, economic, and personal problems (Grant et al., 2015).”
InfluentialImpulsivity as a determinant and consequence of drug use: a review of underlying processes
de Wit, H. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00129.x · Cited by 1,415
2010 National and State Costs of Excessive Alcohol Consumption
Sacks, J. J., Gonzales, K. R., Bouchery, E. E., Tomedi, L. E., & Brewer, R. D. (2015) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.05.031 · Cited by 1,180 · cited 1×
“Problem drinking costs the U.S. society more than $249 billion annually (Sacks et al., 2015) and causes nearly 88,000 deaths each year (Centers for Disease Control and Prevention, 2013).”
A Role for Brain Stress Systems in Addiction
Koob, G. F. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.012 · Cited by 1,056 · cited 2×
“…have a role in the stress response: corticotropin-releasing factor (CRF), dynorphin, norepinephrine, vasopressin, hypocretin (orexin), and substance P, as well as those that are antistress, including neuropeptide Y, nociceptin (orphanin FQ), and endocannabinoids (Koob, 2008; Koob and Mason, 2016).”
CLARITY for mapping the nervous system
Chung, K., & Deisseroth, K. (2013) · Nature Methods · doi:10.1038/nmeth.2481 · Cited by 747 · cited 2×
“…recording combined with fMRI, optogenetics, and CLARITY, a method that makes brain tissue more transparent, enabling us to observe real-time activity of specific neurons and their projections (Acheson et al., 2014; Chung and Deisseroth, 2013; Deisseroth et al., 2015; Zhu et al., 2015).”
Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300219 · Cited by 571
Addictions neuroclinical assessment: a neuroscience-based framework for addictive disorders
Kwako, L. E., Momenan, R., Litten, R. Z., Koob, G. F., & Goldman, D. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.024 · Cited by 395
Self-citationHeterogeneity of Alcohol Use Disorder: Understanding Mechanisms to Advance Personalized Treatment
Litten, R. Z., Ryan, M. L., Falk, D. E., Reilly, M., Fertig, J. B., & Koob, G. F. (2015) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12669 · Cited by 330 · cited 1×
“In particular, it is important to identify circuits underlying the different domains of AUD and how they are altered during the development of AUD (Luthi and Luscher, 2014).”
Self-citation
Cited by
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“Medication development has been identified as a critical priority for AUD research [283].”
BackgroundFalk, D. E., O’Malley, S. S., Witkiewitz, K., Anton, R. F., Litten, R. Z., Slater, M., Kranzler, H. R., Mann, K. F., Hasin, D. S., Johnson, B., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3079 · Cited by 120
Self-citationGrodin, E. N., Nieto, S. J., Meredith, L. R., Burnette, E., O'Neill, J., Alger, J., London, E. D., Miotto, K., Evans, C. J., Irwin, M. R., et al. (2022) · Addiction Biology · doi:10.1111/adb.13182 · Cited by 25
McCaul, M. E., Wand, G. S., Weerts, E. M., & Xu, X. (2018) · Addiction Biology · doi:10.1111/adb.12511 · Cited by 23
Metadata
- Authors
- Litten, R. Z., Falk, D. E., Ryan, M. L., & Fertig, J. B.
- Venue
- Alcoholism: Clinical and Experimental Research
- Publisher
- Wiley
- Published
- 2016-05-17
- Volume
- 40
- Issue
- 7
- Pages
- 1368-1379
- ISSN
- 0145-6008 (ISSN-L)
- OpenAlex
- W2400828834
- Cited by
- 69
- References
- 17
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development. https://app.cochat.ai/papers/10.1111/acer.13093
- The paper
- Litten, R. Z., Falk, D. E., Ryan, M. L., & Fertig, J. B. (2016). Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development. Alcoholism: Clinical and Experimental Research. https://doi.org/10.1111/acer.13093
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.